BioCryst Pharmaceuticals (BCRX)

P/S ratio as of October 2026 (TTM): 2.20

According to BioCryst Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -4.55. At the end of 2026 the company had a P/S ratio of 2.69.

P/S ratio history for BioCryst Pharmaceuticals from 2001 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	2.69	48.66%
2025	1.81	-49.01%
2024	3.54	-4.28%
2023	3.70	-53.16%
2022	7.90	-50.16%
2021	15.9	-78.53%
2020	73.8	578.44%
2019	10.9	-74.69%
2018	43.0	124.18%
2017	19.2	8.28%
2016	17.7	12.94%
2015	15.7	-75.6%
2014	64.3	148.13%
2013	25.9	842.78%
2012	2.75	-51.66%
2011	5.69	52.58%
2010	3.73	-2.01%
2009	3.80	310.36%
2008	0.9267	-71.87%
2007	3.29	-93.95%
2006	54.4	-98.29%
2005	> 1000	-77.51%
2004	> 1000	18759.03%
2003	74.9	684.31%
2002	9.55	52.86%
2001	6.25

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Gilead Sciences GILD	5.89	167.98%	🇺🇸 USA
GSK plc GSK	2.12	-3.28%	🇬🇧 UK
Sarepta Therapeutics SRPT	0.9261	-57.84%	🇺🇸 USA
Repligen RGEN	13.1	495.40%	🇺🇸 USA
Novavax NVAX	4.19	90.56%	🇺🇸 USA
Celldex Therapeutics CLDX	> 1000	724,918.67%	🇺🇸 USA
NanoViricides NNVC	N/A	N/A	🇺🇸 USA
Cel-Sci CVM	N/A	N/A	🇺🇸 USA
Emergent BioSolutions EBS	0.4352	-80.19%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for BioCryst Pharmaceuticals (BCRX)

P/S ratio as of October 2026 (TTM): 2.20